# A tale of two variants: Spread of SARS-CoV-2 variants Alpha in Geneva, Switzerland, and Beta in South Africa

- <sup>4</sup> Christian L. Althaus<sup>\*a</sup>, Stephanie Baggio<sup>b,c</sup>, Martina L. Reichmuth<sup>a,d</sup>, Emma
- <sup>5</sup> B. Hodcroft<sup>a,e</sup>, Julien Riou<sup>a</sup>, Richard A. Neher<sup>e,f</sup>, Frédérique Jacquerioz<sup>g,h,i</sup>, Hervé
- <sup>6</sup> Spechbach<sup>i</sup>, Julien Salamun<sup>i</sup>, Pauline Vetter<sup>g,j</sup>, Carolyn Williamson<sup>k,l,m</sup>, Nei-yuan
- <sup>7</sup> Hsiao<sup>k,1</sup>, Wolfgang Preiser<sup>n</sup>, Mary-Ann Davies<sup>o,p</sup>, Richard J. Lessells<sup>m,q</sup>, Tulio de
- 8 Olivera<sup>m,q,r</sup>, Laurent Kaiser<sup>g,j</sup>, and Isabella Eckerle<sup>g</sup>
- <sup>9</sup> <sup>a</sup>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- <sup>10</sup> <sup>b</sup>Division of Prison Health, Geneva University Hospitals, Geneva, Switzerland
- <sup>11</sup> <sup>c</sup>Office of Corrections, Department of Justice and Home Affairs of the Canton of Zurich, Zurich, <sup>12</sup> Switzerland
- <sup>13</sup> <sup>d</sup>Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland
- <sup>14</sup> <sup>e</sup>Swiss Institute of Bioinformatics, Basel, Switzerland
- <sup>15</sup> <sup>f</sup>Biozentrum, University of Basel, Basel, Switzerland
- <sup>16</sup> <sup>g</sup>Geneva Center for Emerging Viral Diseases, Geneva University Hospitals and Faculty of
- 17 Medicine, Geneva, Switzerland
- <sup>18</sup> <sup>h</sup>Division of Tropical and Humanitarian Medicine, Geneva University Hospitals and Faculty of
- 19 Medicine, Geneva, Switzerland
- <sup>20</sup> <sup>i</sup>Primary Care Division, Geneva University Hospitals and Faculty of Medicine, Geneva,
- 21 Switzerland
- <sup>22</sup> <sup>j</sup>Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals and
- 23 Faculty of Medicine, Geneva, Switzerland
- <sup>24</sup> <sup>k</sup>Division of Medical Virology, Wellcome Centre for Infectious Diseases Research in Africa & the
- <sup>25</sup> Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town,
- 26 South Africa
- <sup>27</sup> <sup>1</sup>Division of Medical Virology at NHLS Groote Schuur Hospital, University of Cape Town, Cape
- 28 Town, South Africa
- <sup>29</sup> <sup>m</sup>Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa
- <sup>30</sup> <sup>n</sup>Division of Medical Virology, University of Stellenbosch / National Health Laboratory Service
- 31 Tygerberg, Cape Town, South Africa
- <sup>32</sup> <sup>o</sup>Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape
- **Town, South Africa**
- <sup>34</sup> <sup>p</sup>Western Cape Government: Health, Cape Town, South Africa
- <sup>35</sup> <sup>q</sup>KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Department of
- <sup>36</sup> Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa <sup>1</sup>Department of Global Health, University of Washington, Seattle, USA

<sup>\*</sup>Corresponding author: christian.althaus@ispm.unibe.ch

# **37 ABSTRACT**

Several SARS-CoV-2 variants of concern (VOC) are spreading rapidly in different regions of 38 the world. The underlying mechanisms behind their transmission advantage remain unclear. 39 We measured viral load in 950 individuals and found that infections with variant Alpha exhibit a 40 higher viral load and longer viral shedding compared to non-VOC. We then used a transmission 41 model to analyze the spread of variant Alpha in Geneva, Switzerland, and variant Beta in South 42 Africa. We estimated that Alpha is either associated with a 37% (95% compatibility interval, 43 CI: 25–63%) increase in transmissibility or a 51% (95% CI: 32–80%) increase of the infectious 44 duration, or a combination of the two mechanisms. Assuming 50% immune evasion for Beta, 45 we estimated a 23% (95% CI: 10–37%) increase in transmissibility or a 38% (95% CI: 15–78%) 46 increase of the infectious duration for this variant. Beta is expected to outgrow Alpha in regions 47 where the level of naturally acquired immunity from previously circulating variants exceeds 20% 48 to 40%. Close monitoring of Alpha and Beta in regions with different levels of immunity will 49 help to anticipate the global spread of these and future variants. 50

## 51 INTRODUCTION

Novel SARS-CoV-2 variants emerged independently in different geographic regions of the world. 52 According to the definition of the World Health Organization (WHO) as of 25 February 2021, 53 a SARS-CoV-2 variant is defined as a variant of concern (VOC) if it has been demonstrated 54 to be associated with an increase in transmissibility or profound changes in the epidemiology, 55 increased virulence or change in clinical disease presentation; or decrease in effectiveness of 56 public health and social measures or available diagnostics, vaccines, and therapeutics (World 57 Health Organization, 2021). To date, there are four variants identified that fulfill the criteria, 58 namely variant Alpha, first detected in the UK, variant Beta, first detected in South Africa, variant 59 Gamma that emerged in Brazil, and variant Delta, first documented in India. All four variants 60 have become the dominant circulating virus in the affected regions within a short time period, 61 raising concerns about their increased fitness and transmission advantage (Abdool Karim and 62 de Oliveira, 2021). 63 For Alpha, several studies have estimated an increased transmissibility between 40% to 64 100% in the United Kingdom, the United States, Denmark, and Switzerland (Leung et al.,

65 2021; Davies et al., 2021a; Volz et al., 2021; Chen et al., 2021). A higher transmissibility per 66 contact with an infectious person is supported by findings that patients infected with Alpha 67 (or S-gene target failure, SGTF) appear to have lower Ct values (Davies et al., 2021b) and 68 higher viral loads (Ratcliff et al., 2021). A recent study compared 1453 Alpha cases with 977 69 non-Alpha cases and found a 1.0 higher mean  $\log_{10}$  viral load and a 2.6 times higher cell culture 70 replication probability in Alpha cases (Jones et al., 2021). However, others found no differences 71 in viral burden for SGTF (Walker et al., 2021). In addition, preliminary data suggest that Alpha 72 could also be associated with extended periods of viral shedding when compared to previously 73 circulating variants (Kissler et al., 2021). In contrast, evasion from naturally acquired immunity 74 seems to play little to no role for the transmission advantage of Alpha as neutralization by both 75 convalescent sera from previous infections, as well as vaccine-derived antibodies, were able to 76 neutralize Alpha in a similar or only slightly reduced manner (Abdool Karim and de Oliveira, 77 2021). 78

The mechanisms of the transmission advantage of Beta are less well understood. While an
 increased transmissibility and/or a longer infectious duration cannot be ruled out (Pearson et al.,
 2021), the constellation of mutations in the spike receptor-binding-domain (particularly mutation)

E484K and K417N) and the N-terminal domain has been associated with escape from monoclonal antibodies (mAb) and polyclonal serum mediated neutralization (Tegally et al., 2021; Wibmer et al., 2021; Cele et al., 2021; Collier et al., 2021). Gamma, with which Beta shares E484K and other critical mutations, was estimated to evade 21–46% of protective immunity elicited by previous infection with non-VOC (Faria et al., 2021). In order to anticipate the global spread of Alpha, Beta and other variants, it is critically important to understand the consequences of these altered transmission characteristics in different epidemiological settings.

In this study, we aimed at better understanding the mechanisms that result in a transmission 89 advantage of Alpha and Beta. First, we measured viral load in 950 individuals infected with 90 either Alpha or non-VOC. Second, we analyzed the increase in the proportion of Alpha in 91 Geneva, Switzerland, and Beta in South Africa using a transmission model. We then estimated 92 the fitness advantage of the two variants considering the following mechanisms: i) increase 93 in transmissibility, ii) increase of infectious duration, and iii) immune evasion. We compared 94 the fitness advantage of both variants at different levels of naturally acquired immunity, and 95 discussed the implications of our findings for anticipating the further spread of these and other 96 SARS-CoV-2 variants. 97

## 98 METHODS

#### 99 Data

#### 100 Viral load

We assessed individuals presenting at the outpatient SARS-CoV-2 screening site at the Geneva 101 University Hospitals presenting for routine diagnostic SARS-CoV-2 testing. The majority of 102 patients had symptoms compatible with SARS-CoV-2 infection and a small proportion were 103 asymptomatic contacts. All participants were > 16 years old with suspected SARS-CoV-2 104 infection according to the local governmental testing criteria, i.e., suggestive symptoms for 105 coronavirus disease 2019 (COVID-19) and/or recent exposure to a SARS-CoV-2 positive person. 106 We included only nasopharyngeal swabs (NPS) collected from symptomatic patients with known 107 date of symptom onset. We analyzed all NPS samples using the Cobas® SARS-CoV-2 RT-108 PCR assay on the 6800 system (Roche), targeting the E and ORF1 gene, or the TaqPath assay 109 (Thermofisher), targeting the N, ORF1, and S gene. To convert Ct values into SARS-CoV-2 110 RNA copy numbers/ml, we performed serial testing of dilutions of cultured SARS-CoV-2, which 111 were quantified by using in vitro transcribed RNA obtained from the European Virus Archive by 112 using the Charité E gene assay (Corman et al., 2020; Baggio et al., 2020). 113

From 13 January 2021 to 24 March 2021, we re-screened all positive samples with a 114 diagnostic Ct value  $\leq$  32 with a single nucleotide polymorphism (SNP) specific RT-PCRs for 115 mutations 501Y and E484K, allowing to assess presence or absence of the mutation by melting 116 curve analysis (VirSNiP SARS Spike 501Y, VirSNiP SARS Spike E484K, TibMolBiol, Berlin). 117 To identify samples belonging to Alpha, we defined presence of the 501Y mutation and absence 118 of the E484K mutation. Next generation sequencing of a subset of positive specimens confirmed 119 that this combination of mutations correlated with Alpha. In order to increase our sample size 120 for the comparison group for non-VOC viruses, we also included patient samples from the same 121 setting tested from 1 October 2020 to 16 December 2020, a time when no VOCs were circulating 122 in Geneva or Switzerland. We excluded all asymptomatic cases, patients with missing values 123 for date of symptom onset, symptom onset > 12 days, other types of material, and a Ct value of 124 initial diagnostic RT-PCR > 32. 125

#### 126 Viral variants

<sup>127</sup> To track the spread of Alpha in Geneva, Switzerland, we relied on the identification of Alpha <sup>128</sup> described above. To cover the period of November and December 2020, we used sequence data

<sup>129</sup> from randomly chosen samples from Geneva that were submitted to GISAID by the Swiss SARS-

- <sup>130</sup> CoV-2 Sequencing Consortium. The data on the proportion of Alpha in Geneva, Switzerland,
- have been made available on the following website: https://ispmbern.github.io/
- 132 covid-19/variants/. For Beta in South Africa, we retrieved all South African SARS-
- <sup>133</sup> CoV-2 sequences from the GISAID database as of 20 January 2021 (n = 2986, collected from 6
- <sup>134</sup> March 2020 to 6 January 2021) (Shu and McCauley, 2017). We excluded three sequences with
- unknown collection date, leaving 2983 sequences for analysis.

#### 136 Model

Competitive spread between variant and non-variant ('wild-type') strains of SARS-CoV-2 can be described within the susceptible-infected-recovered (SIR) framework by the following two ordinary differential equations:

$$\frac{\mathrm{d}W}{\mathrm{d}t} = \beta SW - \frac{1}{D}W,\tag{1}$$

$$\frac{\mathrm{d}V}{\mathrm{d}t} = (1+\tau)\beta(S+\varepsilon(1-S))V - \frac{1}{(1+\kappa)D}V,\tag{2}$$

where W and V are individuals infected with wild-type and variant, respectively, and S the population of susceptibles.  $\beta$  is the transmission rate and D the infectious duration of the wild-type. The fitness advantage of the variant can act via three different mechanisms:

140 1. Increase in transmissibility: The transmission rate of the variant is increased by the factor 141  $\tau$ .

142 2. Increase of infectious duration: The infectious duration of the variant is increased by the 143 factor  $\kappa$ .

3. *Immune evasion*: The variant can partially evade the acquired immunity from previous infections by the wild-type (1 - S). Immune evasion can vary from complete crossprotection ( $\varepsilon = 0$ ) to full evasion ( $\varepsilon = 1$ ).

One can show that the proportion of the variant among all infections increases according to logistic growth (Marée et al., 2000):

$$p(t) = \frac{V(t)}{W(t) + V(t)} = \frac{1}{1 + \mu e^{-\rho t}},$$
(3)

where  $\mu = W(0)/V(0)$  and  $\rho$  corresponds to the difference in the net growth rates between the variant and the wild-type:

$$\rho = \frac{\frac{\mathrm{d}V}{\mathrm{d}t}}{V} - \frac{\frac{\mathrm{d}W}{\mathrm{d}t}}{W} = (1+\tau)\beta(S+\varepsilon(1-S)) - \frac{1}{(1+\kappa)D} - \beta S + \frac{1}{D}.$$
(4)

Eq. 4 can be solved algebraically for  $\tau$ ,  $\kappa$  or  $\varepsilon$ . If the transmission advantage acts via a single mechanism only, we obtain the following simplified solutions. First, the increased transmissibility of the variant is given by  $\tau = \rho/(\beta S)$ , assuming there is no change in the infectious duration and no immune evasion ( $\kappa = \varepsilon = 0$ ). Since the effective reproduction number of the wild-type is  $R_w = \beta SD$ , we obtain  $\tau = \rho D/R_w$ . Second, the increased infectious duration of the variant is given by  $\kappa = \rho/(1/D - \rho)$ , assuming there is no change in transmissibility and no immune evasion ( $\tau = \varepsilon = 0$ ). Finally, assuming there is no change in transmissibility nor the infectious duration ( $\tau = \kappa = 0$ ), the level of immune evasion is given by  $\varepsilon = \rho/(\beta\Omega) = \rho D(1-\Omega)/(\Omega R_w)$ , where  $\Omega = 1 - S$  corresponds to the proportion of the population with previously acquired immunity against earlier variants, i.e., the cumulative incidence or seroprevalence, at the time the variant starts to grow.

We estimated  $\rho$  by fitting a logistic growth model (binomial regression) to the proportion 158 p(t) of Alpha in Switzerland, Geneva, and Beta in South Africa. To propagate the uncertainty, 159 we constructed 95% compatibility intervals (CIs) for  $\tau$ ,  $\kappa$  and  $\varepsilon$  from 10,000 parameter samples 160 of  $\rho$ , the generation time D, the effective reproduction number of the wild-type  $R_w$ , and the 161 seroprevalence  $\Omega$  (Amrhein et al., 2019). We assumed a normally distributed generation time 162 with a mean of 5.2 days and a standard deviation of 0.8 days (Figure 1A) (Ganyani et al., 2020). 163 We sampled from publicly available estimates of the daily effective reproduction number based 164 on confirmed cases during the early growth phase of the variants in Geneva, Switzerland, (1 165 November 2020 to 31 January 2021; range: 0.58–1.04) and South Africa (1 September 2020 166 to 31 October 2020; range: 0.90-1.12) (https://github.com/covid-19-Re) (Figure 167 1B) (Huisman et al., 2020). In Geneva, Switzerland, seroprevalence was estimated at 21.1% 168 (95% credible interval: 19.2–23.1%; n = 4,000) in samples collected from 23 November 2020 169 to 23 December 2020 (Figure 1C) (Stringhini et al., 2021). In South Africa, seroprevalence was 170 estimated at 30.2% (95% CI: 28.8–31.2%; *n* = 4, 387) in samples collected from 17 August 2020 171 to 25 November 2020 (Shinde et al., 2021). We ignored vaccine-induced immunity as vaccination 172 uptake was still low during the study periods in both countries. All data and R code files are 173 available on GitHub: https://github.com/calthaus/sarscov2-variants. 174





(https://github.com/covid-19-Re) (Huisman et al., 2020). C: Seroprevalence estimates for Geneva, Switzerland (Stringhini et al., 2021), and South Africa (Shinde et al., 2021).

## 175 **RESULTS**

<sup>176</sup> We analyzed viral load in a total of 950 specimens from Geneva, Switzerland (604 non-VOC,

- <sup>177</sup> 346 Alpha). We found a higher mean viral load for Alpha compared to non-VOC (7.4 vs. 6.9
- <sup>178</sup> SARS-CoV-2 log10 RNA copies/ml, p < 0.001) (Figure 2A). Analyzing viral load by day post
- <sup>179</sup> onset of symptoms showed a delayed decrease in viral load for Alpha compared to non-VOC

(Figure 2B). Notably, viral load for non-VOC fell below the threshold for presence of infectious (culturable) virus (10<sup>6</sup> SARS-CoV-2 RNA copies/ml) at day 6 to 11. In contrast, viral load remained above that threshold for B.1.1.7 in samples taken from day 6 to 11 post onset of symptoms. Together, these data suggest that Alpha exhibits a transmission advantage that is mediated by either an increased transmissibility or a longer infectious duration, or a combination of both mechanisms.



**Figure 2.** SARS-CoV-2 viral load for non-VOC and Alpha. A: Comparison of overall viral load. B: Comparison of viral load per day post onset of symptoms. Data: 950 (604 non-VOC, 346 Alpha) individuals from the outpatient screening site at the Geneva University Hospitals, Switzerland. Error bars correspond to the 95% compatibility intervals of the mean. Dashed line: Assumed threshold for presence of infectious virus (10<sup>6</sup> SARS-CoV-2 RNA copies/ml).

Alpha was first detected in Geneva, Switzerland, in a sample from 22 December 2020 and 186 almost completely replaced the previously circulating variants by the end of March 2021 (Figure 187 3A). We estimated the logistic growth rate of the proportion of Alpha at 0.065 (95% CI: 0.060– 188 0.071) per day. This corresponds to either a 37% (95% CI: 25–63%) increase in transmissibility 189 or a 51% (95% CI: 32–80%) increase of the infectious duration. As expected, immune evasion 190 alone can be ruled out as an explanation for the observed spread of Alpha as seroprevalence 191 levels in Geneva were not high enough even if evasion was complete (94% of parameter samples 192 resulted in  $\varepsilon > 1$ ) (Figures 4B and C). 193

Beta was first detected in South Africa in a sample from 8 October 2020 and practically 194 replaced all previously circulating variants by the end of December 2020 (Figure 3B). We 195 estimated the logistic growth rate of the proportion of Beta at 0.095 (95% CI: 0.085–0.106) per 196 day. This corresponds to either a 49% (95% CI: 34-67%) increase in transmissibility or a 97% 197 (95% CI: 54–187%) increase of the infectious duration. Complete immune evasion alone would 198 require a seroprevalence level of 33% (95% CI: 25-40%) to explain the spread of B.1.351, which 199 is only slightly higher than the estimated level of 30% in South Africa. Nevertheless, since 78% 200 of parameter samples resulted in  $\varepsilon > 1$  (Figures 4E and F), we conclude that Beta is likely to be 201 associated with an increased transmissibility and/or an increased infectious duration in addition 202 to partial immune evasion. 203

Based on our analysis, it is not possible to quantify the degree of immune evasion for Beta



**Figure 3.** Increase in the proportion of SARS-CoV-2 variants among confirmed cases. A: Alpha in Switzerland, Geneva. B: Beta in South Africa. Error bars and shaded areas correspond to 95% compatibility intervals of the data (blue) and model (red), respectively.

(Figures 4E and F). An analysis of Gamma – which shares E484K with Beta – in Brazil estimates
that this variant evades 25–61% of protective immunity elicited by previous infection with other
variants (Faria et al., 2021). Assuming 50% immune evasion for Beta, we estimated an additional
23% (95% CI: 10–37%) increase in transmissibility or a 38% (95% CI: 15–78%) increase of the
infectious duration, which is less than for Alpha without immune evasion (Figures 4E and F).

In regions where both Alpha and Beta are present, the existing level of protective immunity 210 against previously circulating variants, i.e., the cumulative incidence or seroprevalence, may 211 influence which variant will outgrow the other, although transmission heterogeneity and other 212 epidemic drivers will mediate this. We estimated the expected growth advantage of both variants 213 as a function of seroprevalence, assuming no immune evasion for Alpha and varying levels of 214 immune evasion for Beta (Figure 5). Depending on the level of immune evasion, Beta is expected 215 to outgrow Alpha when the level of naturally acquired immunity against previously circulating 216 variants exceeds 20% to 40%. 217

## 218 DISCUSSION

We used clinical and epidemiological data to better understand the mechanisms and implications 219 of the transmission advantage of the SARS-CoV-2 variants Alpha and Beta. We found that Alpha 220 infections exhibit a higher viral load and longer viral shedding compared to non-VOC. Using a 221 transmission model, we estimated that Alpha is either associated with a 37% (95% CI: 25-63%) 222 increase in transmissibility or a 51% (95% CI: 32-80%) increase of the infectious duration. 223 Assuming that Beta results in partial immune evasion, we estimated that Beta exhibits a lower 224 increase in transmissibility and/or the infectious duration compared to Alpha. Nevertheless, our 225 analysis suggests that Beta might be expected to outgrow Alpha in regions where the level of 226 naturally acquired immunity against previously circulating variants exceeds 20% to 40%. 227

A strength of our study is the combination of clinical and epidemiological data to analyze the mechanisms and the epidemiological implications of the transmission advantage of Alpha and Beta. The transmission model allowed us to study the competitive spread between variant and non-variant strains of SARS-CoV-2 within the framework of evolutionary and population biology. We considered multiple uncertainties, such as the underlying epidemic dynamics and



**Figure 4.** Relationship between increase in transmissibility, increase of infectious duration, and immune evasion. Top row: Alpha in Geneva, Switzerland. Bottom row: Beta in South Africa. Lines and shaded areas correspond to the median and 95% compatibility intervals.



**Figure 5.** Growth advantage of Alpha and Beta over 'wild-type' variants of SARS-CoV-2. For Alpha, we assumed no immune evasion ( $\varepsilon = 0$ ), i.e., the growth advantage is constant and independent of the seroprevalence. For Beta, we assumed immune evasion of 25% (A), 50% (B), and 75% (C). The growth advantage is relative to a 'wild-type' variant with  $R_w = 1$ . Lines and shaded areas correspond to the median and 95% compatibility intervals.

the level of population immunity.

Our study has a number of limitations. First, we inferred specimens from Geneva, Switzerland, as being Alpha by using mutation specific RT-PCR only. However, NGS surveillance of circulating variants in Switzerland confirmed that presence of 501Y was closely correlated with Alpha. Second, we only included samples with a Ct value  $\leq$  32 to account for testing selection

for mutation specific RT-PCR, so absolute viral loads could be biased towards higher values. 238 Third, the threshold for infectious virus (10<sup>6</sup> SARS-CoV-2 RNA copies/ml) was assessed for 239 non-VOC at the beginning of the pandemic (Wölfel et al., 2020; L'Huillier et al., 2020). As 240 no experimental data on this threshold have been published for Alpha, we assumed that Alpha 241 shows a similar pattern for the presence of culturable virus compared to non-VOC. Fourth, the 242 transmission model did not allow us to quantify the individual contribution of the different 243 mechanisms to the transmission advantage. Fifth, we assumed an exponentially distributed 244 generation time for estimating the increase in transmissibility. A delta distributed generation 245 time would result in slightly higher estimates (Davies et al., 2021a; Volz et al., 2021; Chen et al., 246 2021). Sixth, estimates of the effective reproduction number based on confirmed cases come with 247 considerable uncertainty. We took this uncertainty into account by sampling from daily estimates 248 over a period of 2 to 3 months. Finally, we used seroprevalence estimates from single studies 249 (South Africa not being based on population representative sampling) and did not consider an 250 increase of seroprevalence during the early growth phase of the variants, heterogeneity across 251 the population, or a potential waning of antibodies. 252

Our findings support the notion that the transmission advantage of Alpha is likely to be 253 mediated via a higher viral load (increase in transmissibility) and/or longer viral shedding 254 (increase of infectious duration). The estimated increase in transmissibility for B.1.1.7 is in good 255 agreement with the lower end of earlier estimates (Leung et al., 2021; Davies et al., 2021a; Volz 256 et al., 2021; Chen et al., 2021). In addition, we also estimated a potential increase of the infectious 257 duration, i.e., the generation time. These findings have important implications for infection 258 control. A higher transmissibility per contact requires an additional reduction in contacts to 259 prevent further spread. In contrast, the transmission advantage of a longer infectious duration 260 could be compensated by early case finding and isolation, particularly in low incidence settings 261 with efficient contact tracing capacities. The typically used isolation period also appears to be 262 sufficient for Alpha, as no considerable increase in SARS-CoV-2 infections among healthcare 263 workers has been reported. 264

Immune evasion is arguably of bigger concern than increases in transmissibility or the in-265 fectious duration, especially if there is similar evasion of vaccine-elicited immunity. Similar to 266 Gamma, Beta appears to exhibit partial immune evasion. The finding that Beta is not expected 267 to outgrow Alpha in regions where the cumulative incidence of infections with previously cir-268 culating variants does not exceed 20% is in agreement with the observation that Beta does not 269 seem to replace Alpha in Switzerland or Denmark (https://cevo-public.github.io/ 270 Quantification-of-the-spread-of-a-SARS-CoV-2-variant, https://www. 271 covid19genomics.dk). Similarly, it has been shown that Gamma does not seem to be able 272 to outcompete Alpha in Italy (Stefanelli et al., 2021). On the other hand, Alpha might not be 273 able to outcompete Beta in South Africa. Hence, Beta might outgrow Alpha in some areas of 274 Europe that experience a high cumulative incidence of SARS-CoV-2 in 2020. 275

Our study helps to understand the consequences of the altered transmission characteristics 276 of Alpha and Beta in different epidemiological settings. The presented modeling framework, 277 which considers three different mechanisms that result in a transmission advantage of VOCs, 278 can be readily applied to data sets from other regions and countries. More research is needed to 279 better understand how VOCs affect symptomaticity and disease severity, and how they respond to 280 cellular and humoral immune responses elicited by natural infection and vaccines. We conclude 281 that the further spread of Alpha and Beta will strongly depend on the level of acquired immunity 282 from previously circulating variants. Hence, it will be important to closely monitor the spread 283 of these and other VOCs in regions with varying levels of naturally acquired immunity and 284 vaccination uptake. 285

### 286 Acknowledgments

We would like to thank the Network for Genomic Surveillance in South Africa (NGS-SA) which includes the National Health Laboratory Service, the National Institute for Communicable

<sup>289</sup> Diseases, the University of Cape Town, Stellenbosch University, the University of Free State, and

the KwaZulu-Natal Research Innovation & Sequencing Platform at the University of KwaZulu-Natal.

## 292 Funding

<sup>293</sup> CA received funding from the European Union's Horizon 2020 research and innovation pro-<sup>294</sup> gramme - project EpiPose (No 101003688). CA, RN and EH received funding from the Swiss

National Science Foundation (grant 196046). IE received funding from the Swiss National

Foundation (grant 196644 and 196383) and the Private HUG Foundation by the Pictet Charita-

<sup>297</sup> ble Foundation. NGS-SA was supported by the Strategic Health Innovation Partnerships Unit

<sup>298</sup> of the South African Medical Research Council, with funds received from the South African

<sup>299</sup> Department of Science and Innovation.

## 300 Competing interests

<sup>301</sup> The authors declare no competing interests.

# 302 **REFERENCES**

Abdool Karim, S. S. and de Oliveira, T. (2021). New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. *N Engl J Med*.

Amrhein, V., Greenland, S., and McShane, B. (2019). Scientists rise up against statistical significance. *Nature*, 567(7748):305–307.

Baggio, S., L'Huillier, A. G., Yerly, S., Bellon, M., Wagner, N., Rohr, M., Huttner, A., Blanchard-

Rohner, G., Loevy, N., Kaiser, L., Jacquerioz, F., and Eckerle, I. (2020). SARS-CoV-2 viral
 load in the upper respiratory tract of children and adults with early acute COVID-19. *Clin*

310 Infect Dis.

Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S.,
Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B.,
Gosnell, B. I., Hanekom, W., Moosa, M.-Y. S., Lessells, R. J., de Oliveira, T., Sigal, A.,

NGS-SA, and Team, C.-K. (2021). Escape of SARS-CoV-2 501Y.V2 from neutralization by

- convalescent plasma. *Nature*.
- <sup>316</sup> Chen, C., Nadeau, S., Topolsky, I., Manceau, M., Huisman, J. S., Jablonski, K. P., Fuhrmann, L.,
  <sup>317</sup> Dreifuss, D., Jahn, K., Beckmann, C., Redondo, M., Kobel, O., Noppen, C., Risch, L., Risch,
- M., Wohlwend, N., Kas, S., Bodmer, T., Roloff, T., Stange, M., Egli, A., Eckerle, I., Denes, R.,
- Feldkamp, M., Nissen, I., Santacroce, N., Burcklen, E., Aquino, C., de Gouvea, A. C., Moccia,
- M. D., Grüter, S., Sykes, T., Opitz, L., White, G., Neff, L., Popovic, D., Patrignani, A., Tracy,
- J., Schlapbach, R., Dermitzakis, E. T., Harshman, K., Xenarios, I., Pegeot, H., Cerutti, L., Penet, D., Blin, A., Elies, M., Althaus, C., Beisel, C., Beerenwinkel, N., Ackermann, M., and

Penet, D., Blin, A., Elies, M., Althaus, C., Beisel, C., Beerenwinkel, N., Ackermann, M., and
 Stadler, T. (2021). Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland.
 *medRxiv*.

- <sup>325</sup> Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S,
- S. A., Bassi, J., Pinto, D., Fregni, C. S., Bianchi, S., Tortorici, M. A., Bowen, J., Culap, K.,
- Jaconi, S., Cameroni, E., Snell, G., Pizzuto, M. S., Pellanda, A. F., Garzoni, C., Riva, A.,
- CITIID-NIHR BioResource COVID-19 Collaboration, Elmer, A., Kingston, N., Graves, B.,
- McCoy, L. E., Smith, K. G. C., Bradley, J. R., Temperton, N., Lourdes Ceron-Gutierrez, L.,
- Barcenas-Morales, G., COVID-19 Genomics UK (COG-UK) consortium, Harvey, W., Virgin,

- H. W., Lanzavecchia, A., Piccoli, L., Doffinger, R., Wills, M., Veesler, D., Corti, D., and
- Gupta, R. K. (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature*.
- Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Bleicker, T.,
- Brünink, S., Schneider, J., Schmidt, M. L., Mulders, D. G., Haagmans, B. L., van der Veer, B.,
- van den Brink, S., Wijsman, L., Goderski, G., Romette, J.-L., Ellis, J., Zambon, M., Peiris,
- M., Goossens, H., Reusken, C., Koopmans, M. P., and Drosten, C. (2020). Detection of 2019 novel coronavirus (2019-ncov) by real-time rt-pcr. *Euro Surveill*, 25(3).
- Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson,
- C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T., Gimma, A., Waites,
- W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., CMMID COVID-19 Working Group,
- COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz, K., Keogh, R., Eggo, R. M.,
- <sup>343</sup> Funk, S., Jit, M., Atkins, K. E., and Edmunds, W. J. (2021a). Estimated transmissibility and
- impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*.
- Davies, N. G., Jarvis, C. I., CMMID COVID-19 Working Group, Edmunds, W. J., Jewell, N. P.,
   Diaz-Ordaz, K., and Keogh, R. H. (2021b). Increased mortality in community-tested cases of
- 347 SARS-CoV-2 lineage B.1.1.7. *Nature*.
- <sup>348</sup> Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. d. S., Mishra, S., Crispim,
- M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., Hulswit, R. J. G., Franco, L. A. M.,
- Ramundo, M. S., de Jesus, J. G., Andrade, P. S., Coletti, T. M., Ferreira, G. M., Silva, C.
- A. M., Manuli, E. R., Pereira, R. H. M., Peixoto, P. S., Kraemer, M. U. G., Gaburo, Jr, N.,
- Camilo, C. d. C., Hoeltgebaum, H., Souza, W. M., Rocha, E. C., de Souza, L. M., de Pinho,
- M. C., Araujo, L. J. T., Malta, F. S. V., de Lima, A. B., Silva, J. d. P., Zauli, D. A. G., Ferreira, A. C. d. S., Schnekenberg, R. P., Laydon, D. J., Walker, P. G. T., Schlüter, H. M., Dos Santos,
- A. C. d. S., Schnekenberg, R. P., Laydon, D. J., Walker, P. G. T., Schlüter, H. M., Dos Santos, A. L. P., Vidal, M. S., Del Caro, V. S., Filho, R. M. F., Dos Santos, H. M., Aguiar, R. S.,
- A. L. P., Vidal, M. S., Del Caro, V. S., Filho, R. M. F., Dos Santos, H. M., Aguiar, R. S.,
   Proença-Modena, J. L., Nelson, B., Hay, J. A., Monod, M., Miscouridou, X., Coupland, H.,
- Sonabend, R., Vollmer, M., Gandy, A., Prete, Jr, C. A., Nascimento, V. H., Suchard, M. A.,
- Bowden, T. A., Pond, S. L. K., Wu, C.-H., Ratmann, O., Ferguson, N. M., Dye, C., Loman,
- N. J., Lemey, P., Rambaut, A., Fraiji, N. A., Carvalho, M. d. P. S. S., Pybus, O. G., Flaxman,
- S., Bhatt, S., and Sabino, E. C. (2021). Genomics and epidemiology of the p.1 sars-cov-2
- <sup>361</sup> lineage in manaus, brazil. *Science*.
- Ganyani, T., Kremer, C., Chen, D., Torneri, A., Faes, C., Wallinga, J., and Hens, N. (2020).
   Estimating the generation interval for coronavirus disease (COVID-19) based on symptom
- onset data, March 2020. *Euro Surveill*, 25(17).
- Huisman, J. S., Scire, J., Angst, D. C., Neher, R. A., Bonhoeffer, S., and Stadler, T. (2020).
   Estimation and worldwide monitoring of the effective reproductive number of SARS-CoV-2.
   *medRxiv*.
- 368 Jones, T. C., Biele, G., Mühlemann, B., Veith, T., Schneider, J., Beheim-Schwarzbach, J.,
- Bleicker, T., Tesch, J., Schmidt, M. L., Sander, L. E., Kurth, F., Menzel, P., Schwarzer, R.,
- Zuchowski, M., Hofmann, J., Krumbholz, A., Stein, A., Edelmann, A., Corman, V. M., and
- <sup>371</sup> Drosten, C. (2021). Estimating infectiousness throughout SARS-CoV-2 infection course. <sup>372</sup> *Science*.
- Kissler, S. M., Fauver, J. R., Mack, C., Tai, C. G., Breban, M. I., Watkins, A. E., Samant, R. M.,
- Anderson, D. J., Ho, D. D., Grubaugh, N. D., and Grad, Y. H. (2021). Densely sampled
- viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. *medRxiv*.
- Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., and Wu, J. T. (2021). Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to

- <sup>379</sup> November 2020. *Euro Surveill*, 26(1).
- L'Huillier, A. G., Torriani, G., Pigny, F., Kaiser, L., and Eckerle, I. (2020). Culture-Competent
   SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. *Emerg*
- <sup>382</sup> *Infect Dis*, 26(10):2494–2497.
- Marée, A. F., Keulen, W., Boucher, C. A., and De Boer, R. J. (2000). Estimating relative fitness in viral competition experiments. *J Virol*, 74(23):11067–72.
- <sup>385</sup> Pearson, C. A., Russell, T. W., Davies, N., Kucharski, A. J., CMMID COVID-19 working group,
- Edmunds, W. J., and Eggo, R. M. (2021). Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa.
- Ratcliff, J., Nguyen, D., Fish, M., Rhynne, J., Jennings, A., Williams, S., Al-Beidh, F., Bonsall,
   D., Evans, A., Golubchik, T., Gordon, A. C., Lamikanra, A., Tsang, P., Ciccone, N., Leuscher,
- U., Slack, W., Laing, E., Mouncey, P. R., Ziyenge, S., Olivera, M., Ploeg, R., Rowan, K. M.,
- <sup>391</sup> Shankar-Hari, M., Roberts, D. J., Menon, D. K., Estcourt, L., Simmonds, P., and Harvala, H.
- <sup>392</sup> (2021). Virological and serological characterization of critically ill patients with COVID-19
- in the UK: a special focus on variant detection. *medRxiv*.
- Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela,
  M. S. L., Moodley, D., Hanley, S., Fouche, L., Louw, C., Tameris, M., Singh, N., Goga,
- A., Dheda, K., Grobbelaar, C., Kruger, G., Carrim-Ganey, N., Baillie, V., de Oliveira, T.,
- Koen, A. L., Lombaard, J. J., Mngqibisa, R., Bhorat, A. E., Benadé, G., Lalloo, N., Pitsi, A.,
- Vollgraaff, P.-L., Luabeya, A., Esmail, A., Petrick, F. G., Jose, A. O., Foulkes, S., Ahmed,
- K., Thombrayil, A., Fries, L., Cloney-Clark, S., Zhu, M., Bennett, C., Albert, G., Faust, E.,
- <sup>400</sup> Plested, J. S., Robertson, A., Neal, S., Cho, I., Glenn, G. M., Dubovsky, F., Madhi, S. A., and
- (2021). Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351
   Variant. *medRxiv*.
- Shu, Y. and McCauley, J. (2017). GISAID: Global initiative on sharing all influenza data from
  vision to reality. *Euro Surveill*, 22(13).
- Stefanelli, P., Trentini, F., Guzzetta, G., Marziano, V., Mammone, A., Poletti, P., Grané, C. M.,
   Manica, M., del Manso, M., Andrianou, X., Pezzotti, P., Ajelli, M., Rezza, G., Brusaferro, S.,
- <sup>407</sup> Merler, S., and (2021). Co-circulation of SARS-CoV-2 variants B.1.1.7 and P.1. *medRxiv*.
- <sup>408</sup> Stringhini, S., Zaballa, M.-E., Perez-Saez, J., Pullen, N., de Mestral, C., Picazio, A., Pennacchio,
- F., Wisniak, A., Richard, A., Baysson, H., Loizeau, A., Balavoine, J.-F., Trono, D., Pittet,
- D., Posfay-Barbe, K., Flahault, A., Chappuis, F., Kherad, O., Vuilleumier, N., Kaiser, L.,
   Azman, A. S., Guessous, I., and Specchio-COVID19 Study Group (2021). Seroprevalence of
- Azman, A. S., Guessous, I., and Specchio-COVID19 Study Group (2021). Seropre
- anti-SARS-CoV-2 antibodies after the second pandemic peak. *Lancet Infect Dis.*
- <sup>413</sup> Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D.,
- Pillay, S., San, E. J., Msomi, N., Mlisana, K., von Gottberg, A., Walaza, S., Allam, M., Ismail,
  A., Mohale, T., Glass, A. J., Engelbrecht, S., Van Zyl, G., Preiser, W., Petruccione, F., Sigal,
- A., Hardie, D., Marais, G., Hsiao, M., Korsman, S., Davies, M.-A., Tyers, L., Mudau, I., York,
- D., Maslo, C., Goedhals, D., Abrahams, S., Laguda-Akingba, O., Alisoltani-Dehkordi, A.,
- Godzik, A., Wibmer, C. K., Sewell, B. T., Lourenço, J., Alcantara, L. C. J., Kosakovsky Pond,
- S. L., Weaver, S., Martin, D., Lessells, R. J., Bhiman, J. N., Williamson, C., and de Oliveira, T.
- (2021). Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein.
- 421 Nature.
- Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R.,
- Laydon, D. J., Dabrera, G., O'Toole, Á., Amato, R., Ragonnet-Cronin, M., Harrison, I.,
- Jackson, B., Ariani, C. V., Boyd, O., Loman, N. J., McCrone, J. T., Gonçalves, S., Jorgensen,
- D., Myers, R., Hill, V., Jackson, D. K., Gaythorpe, K., Groves, N., Sillitoe, J., Kwiatkowski,
- D. P., COVID-19 Genomics UK (COG-UK) consortium, Flaxman, S., Ratmann, O., Bhatt, S.,

- Hopkins, S., Gandy, A., Rambaut, A., and Ferguson, N. M. (2021). Assessing transmissibility
  of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*.
- Walker, A. S., Vihta, K.-D., Gethings, O., Pritchard, E., Jones, J., House, T., Bell, I., Bell, J. I.,
- Newton, J. N., Farrar, J., Diamond, I., Studley, R., Rourke, E., Hay, J., Hopkins, S., Crook, D.,
- Peto, T., Matthews, P. C., Eyre, D. W., Stoesser, N., Pouwels, K. B., and (2021). Increased
- infections, but not viral burden, with a new SARS-CoV-2 variant. *medRxiv*.
- 433 Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B.,
- Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., Rossouw, T., Boswell,
- M., Ueckermann, V., Meiring, S., von Gottberg, A., Cohen, C., Morris, L., Bhiman, J. N.,
- and Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African
- 437 COVID-19 donor plasma. *Nat Med*.
- 438 Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer,
- D., Jones, T. C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T., Brünink, S., Schneider, J.,
- Ehmann, R., Zwirglmaier, K., Drosten, C., and Wendtner, C. (2020). Virological assessment
  of hospitalized patients with COVID-2019. *Nature*, 581(7809):465–469.
- 442 World Health Organization (2021). COVID-19 Weekly Epidemiological Update 25 February
- 443 2015.